Cobra Biologics has been recognised with a CMO Leadership Award 2017 in the five categories Quality, Reliability, Capabilities, Expertise and Compatibility.
Presented last night at a reception dinner at The W Hotel in New York City, the awards are organised by Life Science Leader magazine and recipients determined through customer feedback collected by Industry Standard Research (ISR). This year’s research included survey responses from over 339 biopharma and pharma professionals who utilise contract development and manufacturing services.
In their 6th year, the CMO Leadership Awards provide Life Science Leader magazine’s readers with accurate and reliable customer feedback to assist them in choosing a reputable partner for their development and manufacturing needs.
For the 2017 awards, Life Science Leader teamed up with Industry Standard Research (ISR) to determine the award recipients. More than 80 contract manufactures were assessed by 26 performance metrics in ISR’s annual Contract Manufacturing Quality Benchmarking survey. Survey participants were recruited from pharma and biopharma companies of all sizes and were screened for decision-making influence related to working with contract manufacturing suppliers. Respondents only evaluate companies with which they have worked on an outsourced project within the past 18 months ensuring that survey responses are based on actual involvement with contract manufacturers and clear experiential data.
Peter Coleman, CEO Cobra Biologics commented: “I am delighted that Cobra has been selected for a CMO Leadership Award. I believe our reputation in the market for GMP manufacturing services combined with excellent science, and a close rapport with our customers, are the key reasons for our rapid growth over the last five years as we strive to become a global leader in biologics contract manufacturing.”
Louis Garguilo, Executive Editor, Life Science Leader and OutsourcedPharma.com said: “Each year, the CMO Leadership Awards recognise the success that individual drug development and manufacturing organisations have in serving the needs of their biotechnology and pharmaceutical customers and partners. Recipients are evaluated by the executives and managers at the sponsors the CMOs have worked, in the six critical categories of capabilities, compatibility, expertise, quality, reliability and development. An award in any of these categories adds to the distinction and reputation of CMOs within the greater drug discovery, development, manufacturing and marketing industries.”
Andrew Schafer, President of Industry Standard Research said: “Industry Standard Research is honoured to conduct the research for Life Science Leader’s CMO Awards. ISR’s stringent screening processes and the high calibre of qualification required to participate in our contract manufacturing benchmarking research means that real customers provide experiential feedback on their involvement with contract suppliers over the past 18 months. This enables users of ISR’s research to make confident business decisions based on the experiences of their industry peers.”